Am J Transplant, Volume 16, Suppl 3 Archives - Page 126 of 180 - ATC Abstracts

2016 American Transplant Congress
Soluble Fibrinogen-Like Protein 2 Regulates Differentiation and Enhances Immunosuppressive Function of Myeloid-Derived Suppressor Cells in Allograft Immunity.
C. Yang,^1,4 L. Wang,³ R. Rong,^2,4 T. Zhu,^2,4 M. Xu.^2,4
¹Plastic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China; ²Urology, Zhongshan Hospital, Fudan University, Shanghai, China; ³Biomedical Research Center, Zhongshan Hospital, Fudan University, Shanghai, China; ⁴Shanghai Key Laboratory of Organ Transplantation, Shanghai, China.
Soluble fibrinogen-like protein 2 (sFGL2) is a novel immunoregulatory molecule, secreted mainly by regulatory T cells. CD11b+ Gr1+ myeloid-derived suppressor cells (MDSCs) are an important…
2016 American Transplant Congress
Early De Novo DSA with T Cell Mediated Rejection (TCMR) Is Associated with Allograft Dysfunction with Chronic Injury.
A. Cherukuri, R. Mehta, P. Sood, A. Zeevi, S. Hariharan, D. Rothstein.
UPMC, Pittsburgh.
De novo anti-donor HLA specific antibody (DSA) detected post-renal transplantation is associated with adverse outcomes. However, the relationship between early de novo DSA and subsequent…
2016 American Transplant Congress
Evolving to Everolimus: A Safe and Effective Option for Pancreas Transplant.
S. Yeager, A. Carlson, C. Truax, N. Kenyon, F. Ahmed, J. Corbett, F. Shihab, L. Smith.
University of Utah Health Care, Salt Lake City, UT.
Although everolimus is an attractive option for conversion therapy in pancreas tx pts that experience SE's of commonly used immunosuppression, TAC and MPA, there is…
2016 American Transplant Congress
Risk Factors for Early Readmission After Total Pancreatectomy with Islet Auto Transplantation.
R. Shahbazov,¹ N. Bashoo,² G. Yoshimatsu,² G. Saracino,² F. Azari,¹ N. Onaca,² P. Kim,² M. Levy.³
¹Charles O.Strikler Transplant Center, Department of Surgery, University of Virginia, Charlottesville, VA; ²Baylor Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX; ³Transplant Division, Virginia Commonwealth University, Richmond, VA.
Introduction: Readmission after Total Pancreatectomy with Islet Auto Transplantation (TPIAT) is common, but no data is available on reasons for readmission and islet graft function.Aims:…
2016 American Transplant Congress
Developing a PCR-Based System to Access the Correlation of Local Chimerism and Fate of the Vascularized Composite Allotransplant.
X.-T. Huang,¹ H.-Y. Cheng,¹ C.-F. Lin,¹ S.-S. Qiu,² L.-Y. Shih,¹ F.-C. Wei.^1,2,3
¹Center for Vascularized Composite Allotransplantation, Chang Gung Memorial Hospital, Gueishan, Taoyuan, Taiwan; ²Department of Plastic and Reconstructive Surgery, Chang Gung Memorial Hospital, Gueishan, Taoyuan, Taiwan; ³College of Medicine, Chang Gung University, Gueishan, Taoyuan, Taiwan.
It is established that development of mixed chimerism following allotransplantation is associated with induction of tolerance to allotransplants. Although chimerism in peripheral blood can be…
2016 American Transplant Congress
Measuring Efficacy of Antibody Removal Therapies: Back to Titers.
A. Tambur,¹ D. Glotz,² N. Herrera,¹ E. Chatroop,¹ T. Roitberg,¹ J. Friedewald,¹ D. Gjertson.³
¹Northwestern University, Chicago; ²Hopital Saint-Louis, Paris, France; ³UCLA, LA.
The need for reliable tools to predict likelihood of HLA-antibody responses to treatment and to monitor efficacy of antibody removal therapies manifests itself on two…
2016 American Transplant Congress
Poor HLA Matching May Reduce the Beneficial Effect of ABOi Pairs Entering the Paired and Pooled Scheme.
M. Willicombe, C. Lawrence, R. Charif, A. McLean, J. Galliford, D. Taube.
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
Introduction: Paired/pooled donation (PPD) facilitates transplantation between UK donor-recipient pairs who are either HLA or blood group incompatible, in whom transplantation is either contraindicated or…
2016 American Transplant Congress
Recipient Age and KDPI Are Potent Predictors of Early Acute Rejection in the Modern Era of Deceased Donor Kidney Transplantation.
D. Keith, G. Vranic, A. Nishio Lucar.
Medicine, University of Virginia, Charlottesville, VA.
The rate of acute rejection in the first six months after deceased donor (DD) kidney transplant is about 10% in the modern era of immunosuppression.…
2016 American Transplant Congress
Urine-Derived Cell Lines as a Novel Tool for Monitoring Allo-Reactivity in Kidney Transplant Patients.
C. Thieme,¹ B. Weist,¹ M. Schmück,¹ P. Reinke,¹ N. Babel.^1,2
¹Berlin-Brandenburg Center for Regenerative Therapies, University Medicine Berlin, Berlin, Germany; ²Medical Clinic I, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Reactivity of the immune system against donor antigens determines transplant-rejection after transplantation, and analyzing the alloimmune response has been shown to predict acute rejection in…
2016 American Transplant Congress
Transplantation for Hepatocellularcarcinoma Is There a Tumor Size Limit?
A. Daoud, L. Teeter, M. Ghobrial, E. Graviss, S. Mogawer, A. Sholkamy, M. Alshazly, H. Monsour, A. Gaber.
Houston Methodist Hospital, Houston, TX; Cairo University Medical School, Cairo, Egypt; University of Arkansas for Medical Sciences, Little Rock, AR.
Background:The advent of tumor size based criteria (Milan and UCSF) for transplantation of Hepatocellular carcinomas (HCC) has facilitated access of tumor patients to transplantation. Recent…